{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:55:06Z","timestamp":1768002906700,"version":"3.49.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jurology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.juro.2017.05.031","type":"journal-article","created":{"date-parts":[[2017,5,10]],"date-time":"2017-05-10T03:16:04Z","timestamp":1494386164000},"page":"905-912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Effects of Withdrawing \u03b11-Blocker from Combination Therapy with \u03b11-Blocker and 5\u03b1-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics"],"prefix":"10.1097","volume":"198","author":[{"given":"Yoshihisa","family":"Matsukawa","sequence":"first","affiliation":[{"name":"Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Takai","sequence":"additional","affiliation":[{"name":"Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Funahashi","sequence":"additional","affiliation":[{"name":"Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Majima","sequence":"additional","affiliation":[{"name":"Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tokunori","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Momokazu","family":"Gotoh","sequence":"additional","affiliation":[{"name":"Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2017.05.031_bib1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.urology.2004.07.031","article-title":"State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia","volume":"64","author":"Djavan","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.juro.2017.05.031_bib2","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2017.05.031_bib3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1080\/00365590701226036","article-title":"Short-term efficacy and long-term compliance\/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia","volume":"41","author":"Masumori","year":"2007","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.juro.2017.05.031_bib4","first-page":"814","article-title":"Evidence for atrophy and apoptosis in the prostates of men given finasteride","volume":"81","author":"Rittmaster","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.juro.2017.05.031_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clinthera.2007.01.018","article-title":"A review of the clinical efficacy and safety of 5a-reductase inhibitors for the enlarged prostate","volume":"29","author":"Naslund","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.juro.2017.05.031_bib6","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1442-2042.2009.02357.x","article-title":"Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia","volume":"16","author":"Tsukamoto","year":"2009","journal-title":"Int J Urol"},{"key":"10.1016\/j.juro.2017.05.031_bib7","series-title":"Guideline on the Management of Benign Prostatic Hyperplasia (BPH)","author":"McVary","year":"2010"},{"key":"10.1016\/j.juro.2017.05.031_bib8","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1442-2042.2011.02860.x","article-title":"Outline of JUA clinical guidelines for benign prostatic hyperplasia","volume":"18","author":"Homma","year":"2011","journal-title":"Int J Urol"},{"key":"10.1016\/j.juro.2017.05.031_bib9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2013.03.004","article-title":"EAU Guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms, incl. benign prostatic obstruction (BPO)","volume":"64","author":"Oelke","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.05.031_bib10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","article-title":"The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study","volume":"57","author":"Roehrborn","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.05.031_bib11","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.urology.2006.02.042","article-title":"Symptom\u00a0assessment tool for overactive bladder syndrome\u2014overactive bladder symptom score","volume":"68","author":"Homma","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.juro.2017.05.031_bib12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/nau.10066","article-title":"Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies","volume":"21","author":"Sch\u00e4fer","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.juro.2017.05.031_bib13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0302-2838(03)00367-1","article-title":"Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5a-reductase inhibitor dutasteride","volume":"44","author":"Barkin","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.05.031_bib14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0090-4295(01)01201-8","article-title":"Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia","volume":"58","author":"Baldwin","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.juro.2017.05.031_bib15","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/iju.12438","article-title":"Effects of dutasteride on storage and voiding symptoms in male patients with lower urinary tract symptoms as a result of benign prostatic obstruction: the 1-year outcomes from a prospective urodynamic study","volume":"21","author":"Matsukawa","year":"2014","journal-title":"Int J Urol"},{"key":"10.1016\/j.juro.2017.05.031_bib16","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.juro.2013.03.110","article-title":"Effects of silodosin, a selective \u03b11A-adrenoceptor antagonist, on bladder blood flow and bladder function in a rat model of atherosclerosis induced chronic bladder ischemia without bladder outlet obstruction","volume":"190","author":"Goi","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2017.05.031_bib17","first-page":"2470","article-title":"Effect of tamsulosin on bladder blood flow and bladder function in a rat model of bladder over distention\/emptying induced bladder overactivity","volume":"186","author":"Okutsu","year":"2011","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.juro.2017.05.031_bib18","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/aja.2011.5","article-title":"Comparison of the clinical efficacy of medical treatment of symptomatic benign prostatic hyperplasia between normal and obese patients","volume":"13","author":"Lee","year":"2011","journal-title":"Asian J Androl"},{"key":"10.1016\/j.juro.2017.05.031_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1471-2490-14-60","article-title":"Measuring the improvement in health-related quality of life using King's health questionnaire in non-obese and obese patients with lower urinary tract symptoms after alpha-adrenergic medication: a preliminary study","volume":"14","author":"Kim","year":"2014","journal-title":"BMC Urol"},{"key":"10.1016\/j.juro.2017.05.031_bib20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00120-002-0236-9","article-title":"Drug therapy of benign prostatic hyperplasia syndrome with alpha 1-receptor blockers. Basic principles and clinical results","volume":"41","author":"Oelke","year":"2002","journal-title":"Urologe A"},{"key":"10.1016\/j.juro.2017.05.031_bib21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s11934-996-0008-y","article-title":"Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"7","author":"Kasturi","year":"2006","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.juro.2017.05.031_bib22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1464-410X.2006.06102.x","article-title":"Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology","volume":"97","author":"McVary","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2017.05.031_bib23","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.12659\/MSM.896331","article-title":"Obesity and pelvic floor disorders: a review of the literature","volume":"22","author":"Pomian","year":"2016","journal-title":"Med Sci Monit"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534717647141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534717647141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2017.05.031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T05:02:30Z","timestamp":1651208550000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2017.05.031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1016\/j.juro.2017.05.031"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2017.05.031","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Withdrawing \u03b11-Blocker from Combination Therapy with \u03b11-Blocker and 5\u03b1-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics","name":"articletitle","label":"Article Title"},{"value":"The Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.juro.2017.05.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.","name":"copyright","label":"Copyright"}]}}